News
-
COLD AGGLUTININ DISEASE | Enjaymo Improves Life Quality And Lessens Fatigue, According to Phase 3 Trial Results
These findings “further augment the primary efficacy outcomes of the placebo-controlled Phase 3 CADENZA study, demonstrating that in addition to providing improvements in hematologic [blood-related] parameters, treatment with [Enjaymo] also…
Read More » -
IRON CONTROL | Disc Medicine And Mabwell Sign Deal For Licence To Antibodies Portfolio
Disc plans to initiate a phase 1 trial in healthy volunteers in the second half of 2023. MWTX-003 has the potential to address a wide range of hematologic disorders including…
Read More » -
HSCT | Briquilimab Granted Orphan Drug Designation By The European Commission
Previously, the U.S. Food and Drug Administration (FDA) granted orphan drug designation to briquilimab in HCT, as well as rare pediatric disease designation for the treatment of severe combined immunodeficiency…
Read More » -
NEW APPROVAL | Health Canada Grants Approval To Sobi’s PNH Therapy
The treatment is indicated for such patients with insufficient response to, or are not tolerant to, a C5 inhibitor. The latest development is based on the findings from the head-to-head…
Read More » -
CLINICAL UPDATE | Graphite’s Hopes For Sickle Cell Cure Blunted After First Patient Dosed Experiences Serious Event
The company cited a “serious adverse event in the first patient dosed” with its gene therapy nulabeglogene autogedtemcel (nula-cel) as part of a phase 1/2 trial for SCD. The event is likely to…
Read More » -
RARE ANAEMIAS | Shining a Spotlight on Rare Anaemias’ Education and Advocacy with RAIN
Recognising the absence of a global umbrella organisation for rare anaemias to advocate and safeguard the rights of patients in a consistent way, and the commonalities between rare anaemias in…
Read More » -
CLINICAL UPDATE | Novartis Builds Case for Iptacopan as Oral Rival to PNH Injectables
On December 8, the Swiss pharma group announced that the top-line results of the APPOINT-PNH clinical trial showed that iptacopan provided “clinically meaningful” increases in haemoglobin levels in patients with…
Read More » -
SCIENCE NEWS | Research On Rare Genetic Disease Sheds Light On A Common Head And Neck Cancer
Patients with the rare genetic disorder Fanconi anemia lack certain elements of this repair system, making their cells incapable of removing lesions created by DNA-damaging chemicals, called aldehydes. And…
Read More » -
PROFILE | After Major Advances In Hematology, Dr David Bodine Retires
When David M. Bodine, Ph.D., arrived at the US National Institutes of Health (NIH) for a postdoctoral fellowship in Arthur Nienhuis’s laboratory in the National Heart, Lung and Blood Institute (NHLBI),…
Read More » -
CLINICAL NEWS | First Cohort of Patients Dosed In Phase 2 Study Of KP104 In PNH
KP104 is a first-in-class, bifunctional biologic designed to modulate complement activity through selective targeting of key intervention points in the alternative and terminal complement pathways. On July 28, 2022, the…
Read More »